Sign in

    Raju Prasad

    Research Analyst at William Blair

    Raju Prasad, Ph.D., was most recently a Partner and Senior Biotechnology Analyst at William Blair, specializing in cell therapy, gene therapy, and gene editing, with broad coverage across small-cap to large-cap biotech companies. He led William Blair’s sector coverage expansions and is recognized for launching analytical initiatives in innovative therapeutic areas. During his tenure from March 2014 to March 2023, Prasad became a key opinion leader in biotech equity research, prior to which he held research roles at UNC Chapel Hill and consulted for the U.S. Environmental Protection Agency. He holds a B.A. in cell biology and neuroscience from Rutgers, an M.S. in exercise physiology from the University of Delaware, and a Ph.D. in environmental sciences and engineering from UNC Chapel Hill, and was integral to William Blair’s reputation in deep scientific diligence and market insight.

    Raju Prasad's questions to ROCKET PHARMACEUTICALS (RCKT) leadership

    Raju Prasad's questions to ROCKET PHARMACEUTICALS (RCKT) leadership • Q2 2021

    Question

    Raju Prasad asked about the clinical progression plan for the Danon program now that the high dose is discontinued, specifically regarding adult versus pediatric populations, and requested clarification on changes to the immunosuppression regimen.

    Answer

    CEO Gaurav Shah stated the company intends to move forward immediately with the pediatric population at the low dose. Regarding the immunosuppression regimen, he described the changes as refinements and tightening of the protocol but declined to provide specifics during an active dialogue with the FDA.

    Ask Fintool Equity Research AI

    Raju Prasad's questions to Boundless Bio (BOLD) leadership

    Raju Prasad's questions to Boundless Bio (BOLD) leadership • Q1 2019

    Question

    Raju Prasad of William Blair asked about the doses used in the AT845 non-GLP study, the strategic decision on the CASQ2-CPVT program, and the potential cost savings from in-house plasmid manufacturing.

    Answer

    Matt Patterson, Chairman and CEO, confirmed that multiple relevant doses were used in the AT845 non-GLP study, boosting confidence for future studies. He explained that the CPVT program is being out-licensed due to a smaller-than-expected patient population and a strategic shift to focus on neuromuscular diseases. Regarding plasmid manufacturing, he did not provide specific numbers but stated it is a powerful investment that significantly reduces costs, timelines, and supply chain risk, and will 'pay for itself very rapidly,' confirming plasmid is the most expensive raw material.

    Ask Fintool Equity Research AI

    Raju Prasad's questions to Boundless Bio (BOLD) leadership • Q4 2018

    Question

    Raju Prasad from William Blair & Co. asked about regulatory opinions on patient numbers per jurisdiction, the patient capacity of the 1000L manufacturing scale, and whether the Pompe IND would include non-human primate study data.

    Answer

    President and CEO Matthew Patterson stated that patient numbers per jurisdiction has not been a topic with regulators. He declined to specify patient capacity but reiterated confidence in meeting global demand. He confirmed the Q3 Pompe IND filing will be supported by a completed 12-week non-human primate toxicology study.

    Ask Fintool Equity Research AI